MET and cancer: In cancer models, it was proven that HGF/c-MET is responsible for the resistance to anti-VEGF therapy with sunitinib (VEGFR and PDGFR RTKi), while the concomitant exposure to HGF/c-MET inhibitors and sunitinib abrogated angiogenesis and tumor growth [89].